Micropolis AI Robotics (MCRP) Aegis Capital Financial Conference summary

Product innovation and technology

• Focus on replacing lead acid with UL 1973-compliant lithium iron phosphate batteries, targeting RV, marine, and home energy markets.

• Launched modular and inverter-integrated home energy storage products, with shipments starting in January and contributing to Q1 revenue growth.

• Proprietary battery management system and patented vertical heat technology enhance safety, reliability, and performance.

• Onshoring initiative aims to establish U.S. cell manufacturing, leveraging a 10-year Asian partnership for high-density cells not currently made in the U.S.

• Eleven pending patents and a 12-year warranty support premium positioning and customer trust.

Market expansion and strategy

• RV market rebound is driving incremental revenue, with a 14% increase in shipments and $5 million in expected 2025 revenue from new relationships.

• Home energy storage and cell production are key growth areas, with the home energy market projected at $170 billion and cell market at $200 billion by 2030.

• Strategic partnerships with Camping World and other distributors enable both new equipment and retrofit sales.

• No current tax incentives for U.S.-made batteries in RV sector, but onshoring is expected to improve margins and open government contract opportunities.

• Diversified supply chain includes two main Asian suppliers, with contingency plans for sourcing from Scandinavia or the U.K. if tariffs increase.

Financial performance and outlook

• Achieved fifth consecutive quarter of growth, with Q1 2025 revenues at $2 million, up 111% year-over-year.

• Gross profit margin improved to 24.5% in Q1 2025, aided by inventory strategies and tariff management.

• SG&A expenses reduced by 24.7% compared to the previous quarter through cost controls and warehouse consolidation.

• Market cap is currently less than inventory on hand, with almost no debt, positioning the company for future growth.

• Joint venture for U.S. cell manufacturing will not strain cash reserves, as funding is expected from private or DOE sources, with additional royalty revenue anticipated.